Results of Operations and Financial Condition. On August 12, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended June 30, 2026, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…

The filing is about the approval of an equity incentive plan, not a management change.

Results of Operations and Financial Condition. On May 13, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2026, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…

and Item 7.01, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Termination of Material Definitive Agreement On February 18, 2026, Acrivon Therapeutics, Inc. (the “Company”) announced the completion and certification of its internally, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory, located on premises in Watertown, Massachusetts. With these in-house capabilities, on February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into…

Results of Operations and Financial Condition. On January 8, 2026, Acrivon Therapeutics, Inc. (the “Company”) disclosed that, based on preliminary unaudited financial information, it had preliminary unaudited cash, cash equivalents, and investments of approximately $119 million as of December 31, 2025, which, based on current operating plans, is expected to fund operations into the second quarter of 2027. Because the Company’s consolidated financial statements for the year ended December 31,…

Other Events On January 8, 2026, the Company announced the following clinical data: ACR-368: Potential First-in-Class CHK1 / CHK2 Inhibitor • In Arm 1 of the ACR-368 Phase 2b registrational-intent trial (monotherapy BM+ subjects) an updated interim analysis (EDC data extract as of December 4, 2025) showed a ORR of 39%*. In subjects with ≤2 prior lines of therapy (LoT), the ORR was 44%. Based on data that showed higher response rates in subjects with serous EC (also called uterine serous carci…

Results of Operations and Financial Condition. On November 13, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section…

Results of Operations and Financial Condition. On August 13, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended June 30, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…

Results of Operations and Financial Condition. On May 14, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…

Results of Operations and Financial Condition. On March 25, 2025, Acrivon Therapeutics, Inc. (the “Company”) disclosed a preliminary cash and cash equivalents and short-term investments balance of approximately $184.6 million as of December 31, 2024. Because the Company’s consolidated financial statements for the twelve months ended December 31, 2024 have not yet been finalized, the preliminary statement of the Company’s cash and cash equivalents and short-term investments as of December 31,…

Chief Financial Officer — Rasmus Holm-Jorgensen: The departure of the Chief Financial Officer without specific mention of a successor is considered a significant and negative event.

Results of Operations and Financial Condition. On November 13, 2024, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2024 and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 1…

Results of Operations and Financial Condition. On August 13, 2024, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended June 30, 2024 and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of th…

Results of Operations and Financial Condition. On May 14, 2024, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2024, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…

Results of Operations and Financial Condition. On April 24, 2024, Acrivon Therapeutics, Inc. (the “Company”) disclosed a preliminary cash and cash equivalents and short-term investments balance of approximately $110 million as of March 31, 2024. The Company also disclosed a preliminary pro forma cash and cash equivalents and short-term investments balance of approximately $234 million as of March 31, 2024, after giving effect to the net proceeds of the Company’s private placement previously d…

Other Events. Phase 2b Initial Clinical Data On April 24, 2024, the Company announced initial clinical data from its ongoing registrational-intent Phase 2b clinical trial of ACR-368 in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative). The data presented was as of an April 1, 2024 data cut. A confirmed objective response rate (“ORR”) (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who…

Regulation FD Disclosure. On April 8, 2024, the Company issued a press release announcing the Private Placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any…

Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 8, 2024, Acrivon Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers an aggregate of (i) 8,235,000 shares (t…

Results of Operations and Financial Condition. On March 28, 2024, Acrivon Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…

Director — Santhosh Palani, Ph.D., CFA: Dr. Santhosh Palani was appointed as a director of the company.

Director — Ivana Magovcevic-Liebisch, Ph.D., J.D.: Dr. Ivana Magovcevic-Liebisch was appointed as a director of the company.

Entry into a Material Definitive Agreement On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test. The Third Amendment addresses an expanded scope of work and increases total development milestone payments to Akoya to an aggregate of $17.3 million through pre-market approval b…

and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.